Insider Selling: Gilead Sciences (NASDAQ:GILD) CFO Sells $396,810.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the transaction, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. This trade represents a 1.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Stock Up 0.1%

GILD stock opened at $130.69 on Thursday. Gilead Sciences, Inc. has a twelve month low of $104.46 and a twelve month high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The firm has a market cap of $162.26 billion, a PE ratio of 17.81 and a beta of 0.31. The business has a 50 day moving average of $136.86 and a 200 day moving average of $133.57.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same quarter last year, the company earned $1.81 EPS. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post -0.77 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Maxim Group upgraded Gilead Sciences (GILD) from hold to buy and set a $165 price target, signaling meaningful upside from current levels. Benzinga report on Maxim Group upgrade
• Positive Sentiment: Gilead announced a quarterly dividend of $0.82 per share, reinforcing its appeal as a cash-generating, income-producing biotech with a 2.5% annualized yield.
• Neutral Sentiment: Gilead launched a new $3 billion senior notes offering, which boosts balance-sheet flexibility but also adds to debt financing activity that investors may watch closely. TipRanks article on senior notes
• Neutral Sentiment: Zacks noted that GILD is drawing unusual investor attention, but the item did not include a fresh fundamental catalyst. Zacks trending stock article
• Negative Sentiment: Daiwa Securities trimmed its price target on Gilead to $150 from $161, suggesting some moderation in analyst expectations despite maintaining an outperform rating. MarketScreener report on Daiwa target cut
• Negative Sentiment: Recent insider selling by senior executives, including the CFO, may create a small overhang for sentiment, even though the trades were pre-planned. InsiderTrades report on CFO sale

Institutional Trading of Gilead Sciences

Large investors have recently modified their holdings of the company. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the fourth quarter worth $25,000. Vermillion & White Wealth Management Group LLC grew its holdings in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares during the period. Quattro Advisors LLC bought a new stake in shares of Gilead Sciences in the fourth quarter worth $26,000. Wealth Preservation Advisors LLC grew its holdings in shares of Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares during the period. Finally, Wilkerson Advisory Group LLC grew its holdings in shares of Gilead Sciences by 54.2% in the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 78 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on GILD. Rothschild & Co Redburn reduced their target price on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Deutsche Bank Aktiengesellschaft lifted their target price on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Barclays began coverage on Gilead Sciences in a report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 target price for the company. Cantor Fitzgerald reduced their target price on Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, April 10th. Finally, Argus lifted their target price on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $156.93.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.